The semaglutide label includes a warning about delayed gastric emptying, and pre-existing gastroparesis is a contraindication
Generally, they seek a treatment that is effective but does not disrupt their schedules too much
10.1210/en.2009-1272 5 CarlomagnoF.SalvatoreD.SantoroM.de FranciscisV.QuadroL.PanarielloL.et al (1995)
The hydroxylated benzopyranone core has been confirmed through multimodal spectroscopic techniques, including nuclear magnetic resonance (NMR), mass spectrometry (MS), infrared spectroscopy (IR), and ultravioletvisible spectroscopy (UVVis)
This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
Participation in a regulated UK clinical trial may be an option for some individuals